Compare VIOT & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIOT | GLSI |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 123.9M |
| IPO Year | 2018 | 2020 |
| Metric | VIOT | GLSI |
|---|---|---|
| Price | $1.42 | $29.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 345.7K | ★ 726.4K |
| Earning Date | 03-24-2026 | 11-14-2025 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $385,267,177.00 | N/A |
| Revenue This Year | $42.19 | N/A |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | $3.53 | ★ N/A |
| Revenue Growth | ★ 16.89 | N/A |
| 52 Week Low | $1.18 | $7.78 |
| 52 Week High | $4.33 | $34.10 |
| Indicator | VIOT | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 58.34 |
| Support Level | $1.30 | $24.00 |
| Resistance Level | $1.42 | $32.66 |
| Average True Range (ATR) | 0.09 | 4.13 |
| MACD | 0.04 | -0.47 |
| Stochastic Oscillator | 93.10 | 70.39 |
Viomi Technology Co Ltd, along with its subsidiaries, specializes in the development and sale of Internet-of-Things-enabled smart home products, particularly focusing on home water solutions. The company markets its products in China and generates the majority of its revenue through the sale of smart water purification systems and other connected home devices designed to improve convenience and automation in residential settings. Its product offerings include water purification products, water heaters, smart water kettles, electric kettles, water filters, range hoods, gas stoves, and other small appliances.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.